Kabra Drugs Limited

Equities

KABRADG

INE323K01017

Market Closed - Bombay S.E. Other stock markets 11:00:56 01/07/2024 BST			5-day change	1st Jan Change
7.91 ^INR	0.00%		0.00%	+46.75%

05-30	Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
02-14	Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Kabra Drugs Limited Appoints Pritam Paul as Company Secretary and Compliance Officer

March 18, 2022 at 10:21 am

Kabra Drugs Limited announced that Mr. Pritam Paul has been appointed as a Company Secretary and Compliance Officer of the Company with effect from 18 March, 2022. Mr. Pritam Paul is Company Secretary from Institute of Company Secretaries of India (ICSI).

Latest news about Kabra Drugs Limited

Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-30	CI
Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Kabra Drugs Limited announced that it expects to receive INR 56.905 million in funding	01-22	CI
Kabra Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-13	CI
Kabra Drugs Limited Approves to Shift Registered Office	30/09/23	CI
Kabra Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	08/06/23	CI
Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23	CI
Kabra Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Kabra Drugs Limited Announces Resignation of Muralidharan R as Director	02/11/22	CI
Kabra Drugs Limited Announces Board Appointments	30/09/22	CI
Kabra Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/08/22	CI
Kabra Drugs Limited Announces Executive Changes	07/07/22	CI
Kabra Drugs Limited Announces Appointment of K.N Anand as Additional Director (Independent Director)	09/06/22	CI
Kabra Drugs Limited Announces Resignation of Churchil Durai M Jebastine as Director	30/05/22	CI
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	30/05/22	CI
Kabra Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/05/22	CI
Kabra Drugs Limited Announces Resignation of Pritam Paul as Secretary and Compliance Officer	18/04/22	CI
Kabra Drugs Limited Appoints Pritam Paul as Company Secretary and Compliance Officer	18/03/22	CI
Kabra Drugs Limited Announces the Resignation of Company Secretary and Compliance Officer Radhika Dammani	03/03/22	CI
Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Kabra Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	13/11/21	CI
Kabra Drugs Limited Approves to Shift Registered Office of the Company	30/09/21	CI
Kabra Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	14/08/21	CI
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	29/06/21	CI

Chart Kabra Drugs Limited

Duration

Period

More charts

Company Profile

Sector

Calendar

11/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data